Verseon Corporation (“Verseon” or the “Company”)
Additional Listing and Total Voting Rights
Verseon, a technology-based pharmaceutical company, announces that application has been made for 4,325 new Common Shares of par value $0.001 each (the “Common Shares”) to be admitted to trading on AIM pursuant to the issued restricted stock grants (the "Exercise").
The 4,325 Common Shares are being issued to Dr. Thomas Hecht, Non-Executive Chairman of the Company, in relation to payment of his Director’s fees in the form of restricted stock totalling 17,291 Common Shares vesting quarterly in equal proportions over a one year period. Following Admission, Dr. Hecht will hold 17,291 Common Shares, representing 0.011% of the Company’s issued share capital.
The 4,325 new Common Shares will be issued pursuant to the Exercise and will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on 3 May 2016 ("Admission").
Total Voting Rights
Following Admission, the issued share capital of the Company will consist of 151,385,016 Common Shares. The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 151,385,016. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
|Verseon Corporation||+1 (510) 225 9000|
|Arthur Shmurun / Amy Thai|
|Cenkos Securities (NOMAD and Broker)||+44 (0) 20 7397 8900|
|Christopher Golden / Mark Connelly|
|Abchurch Communications Ltd (PR Advisers)||+44 (0) 20 7398 7719|
|Jamie Hooper / Alex Shaw / Abbie Warner|